To delineate the reason behind a better treatment response and a superior survival outcome conferred by Twist1 overexpression in AML patients, we next used AML cell lines to access their vulnerability to the cytotoxicity of either cytarabine or daunorubicin, the two standard chemotherapeutic agents used in combination during induction treatment for AML patients. Here, TWIST1 is linked to acute myeloid leukemia.